RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRNA)...
Hlavní autoři: | , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2014-09-01
|
Edice: | Cell Reports |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2211124714006172 |